Skip to main content
Premium Trial:

Request an Annual Quote

Biosearch Licenses IP to DuPont for Food Dx Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DuPont Qualicon will have access to Biosearch Technologies' BHQ, CAL Fluor, and Quasar patents under a licensing agreement announced today.

As part of the deal, Biosearch will also manufacture Scorpions primer oligonucleotides for use in food diagnostics by DuPont. This past summer, Biosearch signed an agreement with Qiagen, expanding its rights to the Scorpions primer technology.

Financial terms of the alliance with DuPont were not disclosed.

Biosearch last week entered into a licensing deal with Seegene also covering the BHQ, CAL Fluor, and Quasar technologies.

In a statement announcing today's deal, Marc Beal, director of corporate development for Biosearch, said that it and DuPont's capabilities would deliver "an innovative and exacting molecular diagnostics solution," and added that the company looks forward to working with DuPont as it commercializes BHQ Scorpions-based foodborne pathogen diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.